wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q39061630-BB0CAC42-7770-4D3D-B2DF-57C5E1988032
Q39061630-BB0CAC42-7770-4D3D-B2DF-57C5E1988032
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39061630-BB0CAC42-7770-4D3D-B2DF-57C5E1988032
The landscape of new drugs in lymphoma
P2860
Q39061630-BB0CAC42-7770-4D3D-B2DF-57C5E1988032
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39061630-BB0CAC42-7770-4D3D-B2DF-57C5E1988032
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
5007be8372a89a3d743ecefcac4671ce879df109
P2860
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies